IUPAC_name = 5-(4-Chlorophenyl)-1-(2,4-dichloro-phenyl)-

width = 220
CAS_number = 158681-13-1
ATC_prefix = A08
ATC_suffix = AX01
PubChem = 104850
DrugBank =
molecular_weight = 463.79 g/mol
bioavailability = Undetermined
protein_bound = Nearly 100%
metabolism = Hepatic, CYP3A4 involved
elimination_half-life = Variable:
6 to 9 days with normal BMI
16 days if BMI >30
excretion = Fecal (86%) and renal (3%)
licence_EU = Acomplia
pregnancy_category = Not assigned. Use not recommended
legal_UK = POM
legal_status =
routes_of_administration = Oral

Rimonabant (also known as SR141716, Acomplia, Bethin, Monaslim, Remonabent, Riobant, Slimona, Rimoslim, and Zimulti) [Rimonabant is currently being sold in the United Kingdom by Sanofi-Aventis and in Denmark by Sanofi-Synthelabo under the trade name Acomplia (which is the name used in 18 countries, as of 2007). Bethin, Monaslim, Remonabent, Riobant, Slimona and Rimoslim are generic forms available in India. If approved in the United States, it is intended to be marketed under the name Zimulti.] is an anorectic anti-obesity drug. It is an inverse agonist for the cannabinoid receptor CB1. Its main avenue of effect is reduction in appetite.

Rimonabant is the first selective CB1 receptor blocker to be approved for use anywhere in the world. In Europe, it is indicated for use in conjunction with diet and exercise for patients with a body mass index greater than 30 kg/m², or patients with a BMI greater than 27 kg/m² with associated risk factors, such as type 2 diabetes or dyslipidaemia. In the UK, it has been available since the end of July 2006. As of 2008, the drug was available in 56 countries.


Despite the FDA issuing an approvable letter in February 2006 for the obesity indication and a non-approvable letter for smoking cessation, the drug did not enter the market in the United States in 2006.Facts|date=June 2007 The French pharma firm Sanofi-Aventis disclosed that a complete response to the FDA's approvable letter was submitted on October 26, 2006, triggering a Class I (two-month) or Class II (six-month) review process. On June 13, 2007, FDA's Endocrine and Metabolic Drugs Advisory Committee (EMDAC) concluded that the French manufacturer Sanofi-Aventis failed to demonstrate the safety of rimonabant and voted against recommending the anti-obesity treatment for approval. [ [http://www.acompliareport.com/News/news-061807.htm Zimulti Acomplia Report - Diet Drug Acomplia / Zimulti Gets Thumbs Down From FDA Panel ] ] Subsequently, Sanofi-Aventis announced that it was withdrawing the new drug application (NDA) for rimonabant and that it would resubmit an application at some point in the future.

On 21 June 2006, the European Commission approved the sale of rimonabant in the then 25-member European Union. Sanofi announced that the first country in which Acomplia will be sold is the United Kingdom as a non-prescription drug. Sales began in July 2006. Sanofi also announced that it projects that the drug will be sold shortly thereafter in Denmark, Ireland, Germany, Finland and Norway. It is expected in Belgium [http://www.standaard.be/Artikel/Detail.aspx?artikelId=GN2UC1SD Article from the Belgian newspaper De Standaard] ] and Sweden in 2007. Ordinary obesity will, according to official medical recommendations, not be enough to acquire the prescription in Sweden; there are additional requirements concerning abnormal blood lipid levels. [http://www.tv4.se/nyheter/472499.html Article from the Swedish TV station TV 4 website] ]

The EU's approval was not a blanket approval, nor did it approve Acomplia for non-obesity related problems such as smoking cessation, although off-label use of the drug is still possible. The approval is in combination with diet and exercise for the treatment of obese patients (BMI greater than or equal to 30), or overweight patients (BMI greater than 27) with associated risk factors, such as type 2 diabetes or dyslipidaemia.

ide effects

Shortly after market introduction, press reports and independent studies suggest that side effects occur stronger and more commonly than shown by the manufacturer in their clinical studies. Reports of severe depression are frequent. This is deemed to result from the drug being active in the central nervous system, an area of human physiology so complex that the effects of a drug are extremely difficult to predict or anticipate. [cite web|url=http://www.tagesschau.de/aktuell/meldungen/0,,OID6010180,00.html|title=Kassen müssen nicht für "Acomplia" zahlen|publisher= tagesschau.de|date=2006-10-17|accessdate=2007-06-13]

Because the drug has the opposite effects of cannabinoid receptor agonists such as tetrahydrocannabinol (THC, one of the substances found in marijuana), which is neuroprotective against excitotoxicity, [http://www.jneurosci.org/cgi/content/abstract/21/17/6475] Neuroprotection by 9-Tetrahydrocannabinol, the Main Active Compound in Marijuana, against Ouabain-Induced "In Vivo" Excitotoxicity, M. van der Stelt, W. B. Veldhuis, P. R. Bär, G. A. Veldink1, J. F. G. Vliegenthart, and K. Nicolay, The Journal of Neuroscience, September 1, 2001 ] it can be theorized that Rimonabant promotes the development of neurodegenerative diseases of the central nervous system such as Multiple sclerosis, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), Parkinson's disease, and Huntington's disease in persons who are susceptible.Kim AH, Kerchner GA, and Choi DW. Blocking Excitotoxicity. Chapter 1 in "CNS Neuroproteciton". Marcoux FW and Choi DW, editors. Springer, New York. 2002. Pages 3-36 ] The reported development of previously clinically silent multiple sclerosis in one patient taking Rimonabant suggests that any patients with an underlying neurological condition should not take Rimonabant, given the neuroprotective role of the endocannabinoid system in many experimental paradigms of neurological disease.

On 15 June 2007 the BBC News reported [ [http://news.bbc.co.uk/2/hi/health/6755665.stm BBC NEWS | Health | Suicide risk fears over diet pill ] ] that a committee advising the US FDA has voted not to recommend the drug's approval because of concerns over suicidality, depression and other related side effects associated with use of the drug.

The risk benefit ratio on the usage of Rimonabant is not yet established, so better alternates can be chosen until FDA gives clearance for the same to avoid possible side effects.

Other uses

moking cessation

Rimonabant may also be found to be effective in assisting some smokers to quit smoking. Sanofi-Aventis is currently conducting studies to determine the possible value of rimonabant in smoking-cessation therapy. The Studies with Rimonabant and Tobacco Use (STRATUS) Program involves more than 6,000 subjects. STRATUS is designed to explore two smoking-related therapies: first, to use rimonabant directly to aid in smoking cessation; second, to help prevent weight gain in former smokers. Initial results apparently suggest that rimonabant is effective for both uses. However, the FDA has explicitly stated to Sanofi-Aventis that without additional studies rimonabant cannot be approved in the United States for smoking cessation therapy.According to Cochrane review in 2007 Rimonabant "may increase the odds of quitting approximately 1(1/2)-fold"cite journal
author=Cahill K, Ussher M
title=Cannabinoid type 1 receptor antagonists (rimonabant) for smoking cessation
journal=Cochrane database of systematic reviews (Online)
] .


Rimonabant reduced resumption of cocaine-seeking responses triggered by two of the three most common triggers of relapse in humans, priming and cues. It may also reduce ethanol and opiate seeking behaviorcite journal
author=Maldonado R, Valverde O, Berrendero F
title=Involvement of the endocannabinoid system in drug addiction
journal=Trends Neurosci.
] .


Tetrahydrocannabinol(THC) is known to impair short-term memory. It was therefore hypothesised that Rimonabant may improve short-term memory. Indeed in animal studies it significantly improved the performance of rats to encode information in the short-term memorycite journal
author=Deadwyler SA, Goonawardena AV, Hampson RE
title=Short-term memory is modulated by the spontaneous release of endocannabinoids: evidence from hippocampal population codes
journal=Behavioural pharmacology
] .

Blockade of Cannabis effects

Rimonabant blocks the psychoactive and some of the cardiovascular effects of Δ9-Tetrahydrocannabinol(THC) in humans without affecting the pharmacokineticscite journal
author=Huestis MA, Gorelick DA, Heishman SJ, "et al"
title=Blockade of effects of smoked marijuana by the CB1-selective cannabinoid receptor antagonist SR141716
journal=Arch. Gen. Psychiatry
] .


Wikimedia Foundation. 2010.

Look at other dictionaries:

  • Rimonabant — (SR141716A) Structure du rimonabant (SR141716A) Général Nom IUPAC 5 (4 Chlorophényl) 1 (2,4 dichlorophényl) 4 méthyl N ( …   Wikipédia en Français

  • Rimonabant — Rimonabant …   Wikipedia Español

  • Rimonabant — Strukturformel Allgemeines Freiname Rimonabant Andere Namen …   Deutsch Wikipedia

  • rimonabant — noun An anti obesity drug which acts as an appetite suppressant …   Wiktionary

  • 168273-06-1 — Rimonabant Rimonabant (SR141716A) Structure du rimonabant (SR141716A) Général Nom IUPAC 5 (4 Chlorophényl) 1 (2,4 dichlorophé …   Wikipédia en Français

  • C22H21Cl3N4O — Rimonabant Rimonabant (SR141716A) Structure du rimonabant (SR141716A) Général Nom IUPAC 5 (4 Chlorophényl) 1 (2,4 dichlorophé …   Wikipédia en Français

  • Cannabinoid receptor antagonist — The discovery of the endogenous cannabinoid system led to the development of CB1 receptor antagonists. The first cannabinoid receptor antagonist, rimonabant, was described in 1994. Rimonabant blocks the CB1 receptor selectively and it has been… …   Wikipedia

  • Accomplia — Strukturformel Allgemeines Freiname Rimonabant Andere Namen 5 (4 Chlorphenyl) 1 …   Deutsch Wikipedia

  • Acomplia — Strukturformel Allgemeines Freiname Rimonabant Andere Namen 5 (4 Chlorphenyl) 1 …   Deutsch Wikipedia

  • Anti-obesity medication — Orlistat (Xenic …   Wikipedia

Share the article and excerpts

Direct link
Do a right-click on the link above
and select “Copy Link”

We are using cookies for the best presentation of our site. Continuing to use this site, you agree with this.